Description
Gonadorelin is a synthetic decapeptide structurally identical to natural gonadotropin-releasing hormone (GnRH). GnRH is secreted in pulsatile form by hypothalamic neurons and is the central trigger of gonadotropin release (LH and FSH) from the anterior pituitary. Gonadorelin is thus the most important research tool for studies on HPG axis activation at the pituitary level.
The research mechanism is clearly defined: gonadorelin activates the GnRH receptor (GnRHR) on gonadotrope cells of the anterior pituitary, leading to LH and FSH secretion. A central characteristic of the GnRH axis: secretion must be pulsatile to achieve effective stimulation. Continuous exposure leads in preclinical models to receptor desensitization and thus paradoxically to suppression of gonadotropin release.
This pulsatile characteristic makes gonadorelin a mechanistically interesting compound. In contrast to HCG (which acts on LH receptors in the gonads), gonadorelin acts at the pituitary level, enabling research setups that address endogenous gonadotropin secretion.
With a half-life of approximately 4-10 minutes, it is very short, requiring and reflecting pulsatile research application. In preclinical studies, pump-based setups are frequently used that enable defined pulse intervals.
Gonadorelin is available in 10mg vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Gonadorelin is structurally identical to endogenous GnRH and is considered pharmacologically well understood per study reports, but it acts directly on the pituitary control of the hormone axis.
Observed in research and user reports:
- Pulsatility dependence: continuous rather than pulsatile exposure leads in preclinical models to receptor desensitization and thus paradoxically to suppression of gonadotropin release. The application pattern determines the outcome.
- Hormone axis intervention: by stimulating LH and FSH secretion, the entire HPG axis is addressed, with downstream effects on steroid hormone levels.
- Circulation: isolated reports of brief warmth, mild nausea or headache shortly after application.
- Injection site: redness or pressure at the injection site is among the more common observations.
- No long-term data: robust human studies on longer-term non-clinical use do not exist. The profile rests on clinical diagnostic data and animal models.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone - Science 1978: Classic study in rhesus monkeys with hypothalamic lesions: hourly GnRH pulses reestablished gonadotropin secretion, whereas continuous infusion did not and led to pituitary desensitization.
- Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone - New England Journal of Medicine 1982: Six men with idiopathic hypogonadotropic hypogonadism received low-dose GnRH in pulses via a portable pump: gonadotropins and testosterone rose into the adult range and spermatogenesis was achieved in three participants.
- Gonadotropin-releasing hormone receptors - Endocrine Reviews 2004: Review of the GnRH receptors: in humans, hypothalamic GnRH regulates gonadotropin secretion through the pituitary type I receptor and its Gq coupling.
